{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T23:27:14Z","timestamp":1763767634648,"version":"3.37.3"},"reference-count":34,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1124\/dmd.123.001289","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T08:06:08Z","timestamp":1682064368000},"page":"862-872","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Mass Balance of the Indoleamine 2,3-Dioxygenase Inhibitor Navoximod (GDC-0919) in Rats and Dogs: Unexpected Cyanide Release from Imidazo[5,1-a]isoindole and Species Differences in Glucuronidation"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3282-1343","authenticated-orcid":false,"given":"Shuai","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuguang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoa","family":"Le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven Paul","family":"Hanlon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Binder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Cyrus","family":"Khojasteh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Salphati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.123.001289_bib1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1128\/AAC.03861-14","article-title":"Mass balance, metabolite profile, and in vitro-in vivo comparison of clearance pathways of deleobuvir, a hepatitis C virus polymerase inhibitor","volume":"59","author":"Chen","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.123.001289_bib2","first-page":"199","article-title":"Enzymatic detoxification of cyanide: clues from Pseudomonas aeruginosa Rhodanese","volume":"15","author":"Cipollone","year":"2008","journal-title":"J Mol Microbiol Biotechnol"},{"key":"10.1124\/dmd.123.001289_bib3","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1517\/17425255.2014.876006","article-title":"The role of drug metabolizing enzymes in clearance","volume":"10","author":"Di","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.123.001289_bib4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.apsb.2012.01.002","article-title":"Characterization of ornidazole metabolites in human bile after intravenous doses by ultraperformance liquid chromatography\/quadrupole time-of-flight mass spectrometry","volume":"2","author":"Du","year":"2012","journal-title":"Acta Pharm Sin B"},{"key":"10.1124\/dmd.123.001289_bib5","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/jb\/117.2.392","article-title":"Drug-responsive and tissue-specific alternative expression of multiple first exons in rat UDP-glucuronosyltransferase family 1 (UGT1) gene complex","volume":"117","author":"Emi","year":"1995","journal-title":"J Biochem"},{"key":"10.1124\/dmd.123.001289_bib6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.fct.2018.10.032","article-title":"Metabolism of 4-methylimidazole in Fischer 344 rats and B6C3F1 mice","volume":"123","author":"Fennell","year":"2019","journal-title":"Food Chem Toxicol"},{"key":"10.1124\/dmd.123.001289_bib7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2174\/187231210791292753","article-title":"Application of modern drug metabolism structure determination tools and assays to the in vitro metabolism of imiloxan","volume":"4","author":"Fitch","year":"2010","journal-title":"Drug Metab Lett"},{"key":"10.1124\/dmd.123.001289_bib8","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.3390\/molecules22101729","article-title":"From 2-alkylsulfanylimidazoles to 2-alkylimidazoles: an approach towards metabolically more stable p38\u03b1 MAP kinase inhibitors","volume":"22","author":"Heider","year":"2017","journal-title":"Molecules"},{"key":"10.1124\/dmd.123.001289_bib9","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11095-014-1446-8","article-title":"Quantitative ADME proteomics - CYP and UGT enzymes in the beagle dog liver and intestine","volume":"32","author":"Heikkinen","year":"2015","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.123.001289_bib10","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1124\/dmd.116.072108","article-title":"Utilization of stable isotope labeling to facilitate the identification of polar metabolites of KAF156, an antimalarial agent","volume":"44","author":"Huskey","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001289_bib11","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1158\/1078-0432.CCR-18-2740","article-title":"Phase I study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) administered with PD-L1 inhibitor (atezolizumab) in advanced solid tumors","volume":"25","author":"Jung","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1124\/dmd.123.001289_bib12","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3390\/ijms18030621","article-title":"Revisiting the metabolism and bioactivation of ketoconazole in human and mouse using liquid chromatography-mass spectrometry-based metabolomics","volume":"18","author":"Kim","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1124\/dmd.123.001289_bib13","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/toxsci\/kfx072","article-title":"Uridine diphosphate-glucuronosyltransferase (UGT) 2B subfamily interspecies differences in carnivores","volume":"158","author":"Kondo","year":"2017","journal-title":"Toxicol Sci"},{"key":"10.1124\/dmd.123.001289_bib14","doi-asserted-by":"crossref","first-page":"6705","DOI":"10.1021\/acs.jmedchem.9b00662","article-title":"Discovery of clinical candidate (1R,4r)-4-((R)-2-((S)-6-fluoro-5H-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl)cyclohexan-1-ol (navoximod), a potent and selective inhibitor of indoleamine 2,3-dioxygenase 1","volume":"62","author":"Kumar","year":"2019","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.123.001289_bib15","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s13765-016-0204-5","article-title":"Biotransformation and molecular docking of cyazofamid by human liver microsomes and cDNA-expressed human recombinant P450s","volume":"59","author":"Lee","year":"2016","journal-title":"Applied Biol Chem"},{"key":"10.1124\/dmd.123.001289_bib16","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1111\/bcp.13961","article-title":"Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitor","volume":"85","author":"Ma","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.123.001289_bib17","doi-asserted-by":"crossref","first-page":"364","DOI":"10.2133\/dmpk.DMPK-11-RG-006","article-title":"Hepatic glucuronidation of resveratrol: interspecies comparison of enzyme kinetic profiles in human, mouse, rat, and dog","volume":"26","author":"Maier-Salamon","year":"2011","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.123.001289_bib18","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0090-9556(25)08763-X","article-title":"Metabolism of the antimycotic agent, croconazole, in rabbits","volume":"17","author":"Nakano","year":"1989","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001289_bib19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s40425-018-0351-9","article-title":"Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors","volume":"6","author":"Nayak-Kapoor","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1124\/dmd.123.001289_bib20","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1124\/dmd.107.016030","article-title":"Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects","volume":"35","author":"Ohmori","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001289_bib21","first-page":"2192","article-title":"Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1","volume":"5","author":"Reid","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1124\/dmd.123.001289_bib22","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3109\/00498259009046862","article-title":"Biotransformation of medetomidine in the rat","volume":"20","author":"Salonen","year":"1990","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.123.001289_bib23","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3109\/00498257909042323","article-title":"Metabolic studies of ornidazole in the rat, in the dog and in man","volume":"9","author":"Schwartz","year":"1979","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.123.001289_bib24","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1080\/00498254.2019.1581960","volume":"49","author":"Sharma","year":"2019","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.123.001289_bib25","first-page":"1578","article-title":"Pharmacokinetics and metabolism of a RAS farnesyl transferase inhibitor in rats and dogs: in vitro-in vivo correlation","volume":"29","author":"Singh","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001289_bib26","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/S0006-2952(03)00064-9","article-title":"Cloning and characterisation of the first drug-metabolising canine UDP-glucuronosyltransferase of the 2B subfamily","volume":"65","author":"Soars","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.123.001289_bib27","first-page":"121","article-title":"Evidence for significant differences in microsomal drug glucuronidation by canine and human liver and kidney","volume":"29","author":"Soars","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001289_bib28","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0090-9556(25)06520-1","article-title":"Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members","volume":"23","author":"Stearns","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001289_bib29","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/cpdd.234","article-title":"Absorption, distribution, and excretion of the investigational agent orteronel (TAK-700) in healthy male subjects: a phase 1, open-label, single-dose study","volume":"5","author":"Suri","year":"2016","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1124\/dmd.123.001289_bib30","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/00498250500136692","article-title":"Metabolism of the calmodulin antagonist DY-9760e in animals and humans","volume":"35","author":"Tachibana","year":"2005","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.123.001289_bib31","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1124\/dmd.116.074336","article-title":"Novel mechanism of decyanation of GDC-0425 by cytochrome P450","volume":"45","author":"Takahashi","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001289_bib32","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1124\/dmd.115.067181","article-title":"Elucidating the mechanisms of formation for two unusual cytochrome P450-mediated fused ring metabolites of GDC-0623, a MAPK\/ERK kinase inhibitor","volume":"43","author":"Takahashi","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001289_bib33","doi-asserted-by":"crossref","first-page":"e923","DOI":"10.1371\/journal.pntd.0000923","article-title":"Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness","volume":"4","author":"Torreele","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1124\/dmd.123.001289_bib34","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1124\/dmd.114.059303","article-title":"Dog UDP-glucuronosyltransferase enzymes of subfamily 1A: cloning, expression, and activity","volume":"43","author":"Troberg","year":"2015","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624010109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624010109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.123.001289","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T09:03:27Z","timestamp":1739955807000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624010109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0090955624010109"],"URL":"https:\/\/doi.org\/10.1124\/dmd.123.001289","relation":{},"ISSN":["0090-9556"],"issn-type":[{"type":"print","value":"0090-9556"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mass Balance of the Indoleamine 2,3-Dioxygenase Inhibitor Navoximod (GDC-0919) in Rats and Dogs: Unexpected Cyanide Release from Imidazo[5,1-a]isoindole and Species Differences in Glucuronidation","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.123.001289","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}